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ABSTRACT 
Preeclampsia is a serious pregnancy disorder that is thought to result from the dysregulation of 
placental function and can be detrimental to both the mother and developing fetus. Preeclampsia 
impacts up to 8% of all pregnancies worldwide, yet the factors contributing to the development 
of this disease remain largely unknown. This study set out to test the hypothesis that 
understudied xenobiotic chemicals are capable of reaching the human placenta and disrupting 
critical pathways relevant to placental cell health and preeclampsia. Placentas from a previously 
established cohort of patients with normotensive and preeclamptic pregnancies were analyzed 
using non-targeted approaches to identify unknown molecular features. A total of 29 molecular 
features that represent 27 unique chemicals were statistically associated with preeclampsia 
disease status. One of the identified chemicals showing the largest increase in concentration was 
acetaminophen. Concentrations of acetaminophen were found to be associated with altered 
expression of 27 genes and 57 miRNAs and altered methylation status of 18 genes relevant to 
preeclampsia among the same samples. Acetaminophen-associated genes showed enrichment for 
cell compromise and death-related signaling, which were further characterized through in vitro 
testing with immortalized trophoblasts. This research provides novel evidence towards 
characterizing chemicals in the placental and identified APAP as one of the most significantly 
associated compounds related to preeclampsia. Mechanistic findings showed changes in 
signaling relevant to placental cell damage and death that may be relevant to preeclampsia 
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Chemical exposures during pregnancy can significantly impact maternal and fetal health, 
with potential to lead to serious pregnancy outcomes such as preeclampsia [1]. Preeclampsia 
impacts up to 8% of all pregnancies worldwide, and causes yearly deaths of ~70,000 women and 
~500,000 fetuses, globally [2, 3]. This condition is typically diagnosed by elevated maternal 
blood pressure and maternal proteinuria after approximately 20 weeks of gestation, and often 
forces premature delivery due to maternal risk associated with high blood pressure and 
compromised blood flow to the fetus [4]. There is a current knowledge gap surrounding potential 
risk factors that may impact preeclampsia case status, with expanding evidence supporting the 
potential role of certain pharmaceuticals and environmental chemicals [1, 5, 6]. Furthermore, the 
complete etiology and mechanistic events associated with this disease remain to be fully 
established.  
Chemical exposures that occur during pregnancy contribute to the maternal and fetal 
‘exposome’: the non-genetic factors that may influence pregnancy-related health outcomes [7]. 
Exposures during pregnancy may include complex mixtures of chemicals, a portion of which 
have been shown to reach the placental barrier. For example, various classes of chemicals such 
as pharmaceuticals, metals, per- and polyfluoroalkyl substances, phenols, pesticides, flame 
retardants, and toxins have been measured in maternal serum, cord blood, or placental tissue [8-
13]. Still, the majority of chemicals to which humans are exposed to remain largely understudied 
in relation to toxicological health outcomes, especially with regard to maternal and fetal health 
outcomes [1]. This research gap is of particular concern given the increased vulnerability of 
pregnant women and developing fetuses to potential adverse health outcomes associated with 
various chemical exposures.  
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While the etiology of preeclampsia is thought to be multifactorial, it is well established 
that preeclampsia onset occurs as a result of placental dysfunction [14]. As the barrier between 
the maternal and fetal exposome, the placenta is responsible for the active transport of nutrients 
and oxygen to the developing fetus, and the transfer of waste and other potentially harmful 
elements out [15]. This is achieved in part via the invasion and remodeling of the uterine 
vasculature via trophoblasts, one of the primary cell types in the placenta [16]. However, 
improper placental implantation due to failure of spiral artery transformation may result in 
inadequate blood flow and thus has been linked to preeclampsia [17]. The ability of chemicals to 
reach the placenta and potentially disrupt critical mechanisms of placental health makes it is 
necessary to evaluate this target tissue and better understand links between xenobiotic exposures, 
mechanistic biological responses, and pregnancy outcomes such as preeclampsia.  
This study set out to test the hypothesis that understudied xenobiotics are capable of 
reaching the human placenta and disrupting critical pathways relevant to placental cell health and 
preeclampsia. Using non-targeted measures within placentas collected from preeclamptic and 
normotensive patients, we sought to identify potential chemicals in the placenta that are 
associated with preeclampsia, focusing on those captured by the Agilent Personal Compound 
Database and Library (PCDL). APAP was identified as one of the chemicals most significantly 
increased in concentration in tissues from preeclamptic patients and selected for follow-up 
confirmation, analysis, and in vitro testing. Genomic and epigenomic profiling of the same 
placental tissues identified altered cell signaling relevant to cell death mechanisms associated 
with APAP, which were further characterized in immortalized trophoblasts. These methods 
provide a proof-of-concept for testing chemicals of toxicological interest from non-targeted 
analytical screening.  
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METHODS  
Cohort description and placenta sample collection 
The cohort included in this study consisted of women recruited from the University of North 
Carolina (UNC) hospitals and have been described previously [5, 18, 19]. In brief, participants 
consented to study participation at the time of delivery and consisted of 36 women (17 
normotensive patients and 19 preeclamptic patients). Patients with preeclampsia were identified 
as those exhibiting sustained de novo hypertension (>140/90 mmHg) and proteinuria (³ 300 mg 
of protein within a 24-hour urine collection or a urine protein/creatinine ratio of ³ 0.3mg/dL), 
that developed at ³ 20 weeks of pregnancy, in accordance with the preeclampsia syndrome 
definition by the American Congress of Obstetricians and Gynecologists. For study inclusion, 
preeclamptic patients also had to show either blood pressure >160/110 mmHg, severe neurologic 
complications, or lab abnormalities consistent with HELLP (hemolysis, elevated liver enzymes, 
low platelet count). Subjects were excluded if they had confounding conditions, including pre-
diabetes, diabetes, and gestational diabetes. This research was approved by the Institutional 
Review Board at the University of North Carolina (#11–2054). 
 
Demographic data have been summarized and published previously [18], and are recapitulated 
here in Supplemental Table S1. The majority of participants were non-smokers with primipara. 
Participants consisted of a variety of races, the majority of which were African American (42%) 
or Caucasian (31%). The mean age across the study cohort was 28.3 years. The distributions of 
demographic variables were compared between preeclamptic cases vs. controls, as previously 
detailed [18], and gestational age was the only variable that significantly differed between the 
two groups; preeclamptic patients delivered on average at 32.8 weeks while normotensive 
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patients delivered on average at 38.6 weeks (p<0.01) (Supplemental Table S1). Placenta 
samples were collected after delivery, and full-thickness placental biopsies were acquired, 
avoiding peripheral areas as well as areas of obvious infarction. Biopsies were immediately flash 
frozen in liquid nitrogen and stored at -80°C until further processing. 
 
Placental tissue processing for chemical analyses  
Placenta samples were prepared for chemical analyses by first isolating an approximately 0.5-
gram cross section slice from the middle of each sample. Samples without tissues or analyte were 
extracted in parallel as a method blank. Chemicals were separated from tissue via solid-liquid 
extraction by first adding room temperature H2O: acetonitrile 1:1 to each placenta sample. 
Placenta samples were disrupted and homogenized using a TissueRuptor (Qiagen), vortexed 
vigorously for 5 minutes, and placed in a centrifuge at 4000 rpm for 5 minutes. The resulting 
supernatant was collected and a second round of solid-liquid extraction was performed using 
acetonitrile with 2% formic acid. Samples were vortexed and centrifuged again, and both 
supernatants combined. The combined supernatants were run through solid filtration through a 
Captiva EMR-lipid column, allowing gravity elution and collection of eluates of which 1.0 mL 
was transferred to a liquid chromatography and mass spectrometry vial. For non-targeted 
chemical analysis, 20uL of 1.25ug/mL tracer was added to 1.0 mL of post-filtration eluate for 






Non-targeted analysis of chemicals in placenta extracts  
Liquid extracts of placenta samples were analyzed via liquid chromatography mass spectrometry 
(LCMS) using an Agilent 1290 Infinity II ultra-high-performance liquid chromatograph 
(UHPLC) coupled to an Agilent 6546 high-resolution quadrupole time-of-flight (Q-TOF) mass 
spectrometer with a dual AJS electrospray ionization source. Source parameters were as follows: 
drying gas temperature = 300°C; drying gas flow = 9 L/min; nebulizer gas = 35 psi; sheath gas 
temperature = 350°C; sheath gas flow = 11 L/min; Vcap = 3500V (3000V in negative mode); 
nozzle voltage = 0V (2000V in negative mode); and fragmentor = 100 V. An Agilent Zorbax 
Eclipse Plus C8 (2.1 µm x 100 mm, 1.9 µm). UHPLC column was used for compound separation 
(part number: 959758-906) and the column temperature was set to 40°C. Mobile phases 
consisted of (A) deionized water (Millipore MilliQ Water System) with 0.1% formic acid 
(Fisher) and (B) 90:10 acetonitrile (Alfa Aesar):deionized water with 0.1% formic acid for 
LCMS analyses run in positive ionization mode. For analyses run in negative ionization mode, 
mobile phases were identical with the addition of 0.5 mM ammonium fluoride (Fluka) to both 
mobile phases. The flow rate was set at 0.5 mL/min, and mobile phases were ramped with the 
following gradient: 0-1 min = 5% B; 1-7 min 5-80% B ramp; 7-9 min = 80-90% B ramp; 9-10 
min = 90-100% B ramp; 10-12 min = 100% B; and 12-13.5 min = 5% B. Each sample extract 
was analyzed in full scan mode (MS1) with triplicate injections (2 µL) in each ionization mode. 
A fully randomized run sequence was used, which included replicates of solvent blanks, method 
blanks, and pooled QC samples. For MS1 analysis, the scan range was 100-1000 m/z with a scan 
speed of 2 spectra/sec. A reference solution consisting of purine, 
hexakis(1H,1H,3Htetrafluoropropoxy)phosphazene, and trifluoroacetic acid 
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(TFA) was infused into the source during each run to auto-correct mass drift. Data-dependent 
acquisition MS2 (auto MSMS) was also performed on each sample extract in both positive and 
negative ionization modes, cycling between collision energies of 10, 20, and 40 eV. MS2 data 
were acquired with the following settings: scan range 40-1000 m/z; 6 max precursors per cycle; 
minimum threshold 3000 counts; scan speed 5 spectra/sec, medium isolation width (4 m/z); 
active exclusion enabled after 3 MS2 spectra; exclusion release time 0.2 minutes. MS2 exclusion 
lists were used to exclude ions corresponding to compounds in the reference solution. 
 
HRMS data processing 
MS1 and MS2 feature data were processed separately using a combination of vendor software 
and an NTA web application (hereafter, the “WebApp”) developed by the US EPA.  
 
MS1 Data Processing 
Agilent Profinder software (v.10) was first used to recursively extract and align MS1 molecular 
features across all study samples, pooled QC samples, and method blanks. Here, molecular 
features represent associated m/z peaks corresponding to an unknown compound. All molecular 
features observed in ESI+ mode were initially assumed to be [M+H]+ ion species, and all 
molecular features observed in ESI- mode were initially assumed to be [M-H]- ion species. 
Under these assumptions, grouped m/z peaks for a given feature reflect isotopologue peaks, but 
not fragment, neutral loss, additional adduct (e.g., [M+Na]+), or multimer peaks. The retention 
time (RT) and predicted monoisotopic mass for each molecular feature, along with the observed 
raw intensity of that feature in each study sample and blank, was included in an MS1 output 
table. 
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Separate MS1 output tables for ESI+ and ESI- mode data were loaded into the NTA WebApp,  
along with a file containing experimental and intrinsic property information for the spiked tracer 
compounds. For the current application, the NTA WebApp performed a series of data processing 
procedures to enable subsequent statistical analysis and feature identification. These steps 
include: 1) duplicate feature removal; 2) statistical parameter estimation; 3) data filtering; 4) 
blank subtraction; 5) feature flagging; and 6) tracer compound identification.  
 
For step 1, the NTA WebApp identified and removed superfluous molecular features generated 
via recursive extraction and alignment. For step 2, the NTA WebApp calculated the mean, 
median, standard deviation, and coefficient of variation (CV) of intensity values, along with the 
number of hits across sample and blank replicates, for each feature. These statistical parameter 
estimates were used in Step 3 of WebApp processing for data filtering. Specifically, in Step 3, it 
was required that any given feature, in any given sample, be observed in 2/3 injection replicates 
with a coefficient of variation ≤ 0.80. Sample-specific intensity values not meeting these criteria 
were dropped for that sample only. Any feature not meeting these criteria across all samples was 
dropped from the full dataset. Furthermore, any feature not having a single median sample 
intensity ≥ 3× the median blank intensity was dropped from the full dataset. 
 
After data filtering (Step 3), the median feature intensities for the method blanks were subtracted 
from the median feature intensities for the individual samples. All blank-subtracted values <0 
were set to 0. After blank subtraction (Step 4), a series of calculations was performed by the 
WebApp to flag individual features based on observed characteristics (Step 5). For example, 
molecular features suspected of being adducts of other features (and thus, incorrectly considered 
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as [M+H]+ or [M-H]- ion species during initial processing) were flagged for further manual 
review. Finally, in Step 6, the WebApp extracted all processed data for the spiked tracer 
compounds. Calculations for these compounds (i.e., mass error and RT deviation) were the basis 
for QA/QC evaluation of method performance. 
 
MS2 Data Processing  
Reference MS2 spectra from six Agilent Personal Compound Database and Library (PCDL) 
databases (Environmental water screening, Pesticides, Forensic toxicology, Veterinary drugs, 
Metlin, and Extractables and leachables) were combined into a composite PCDL. For tentative 
chemical candidate identification, experimental MS2 spectra were searched against the 
composite PCDL using Agilent MassHunter Qualitative Analysis software (version B.10) with 
forward and reverse scoring thresholds of 0 and 20, respectively. Spectral matches were 
manually reviewed in order to boost confidence in tentative compound identifications. Results 
from MS2 spectral matching were mapped to processed MS1 features using match tolerances of 
10 ppm for mass accuracy and 0.2 min for RT. 
 
Statistical analysis to identify molecular features associated with preeclampsia  
Processed feature data with tentative chemical identifications (based on PCDL matching) were 
the basis for statistical hypothesis testing across preeclampsia and normotensive sample groups. 
Statistical procedures were performed using SAS statistical software v.9.4 (Cary, NC). Processed 
molecular feature data were not normally distributed. A non-parametric procedure was therefore 
used to test for differences in feature intensities across groups. Specifically, the Wilcoxon two-
sample test was used, considering two-sided t-approximation p-values. Significant differential 
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feature intensity was defined using a false discovery rate (FDR) corrected q-value <0.2 for 
associations with preeclampsia. An additional filter was also applied to consider the magnitude 
of change in feature abundance. For this filter, the overall median intensity was calculated for 
both sample groups, and fold change (FC) in feature abundance was calculated dividing the 
overall median intensity in preeclampsia patients by the overall median intensity in normotensive 
patients. Features not measured in any normotensive patients were assigned a FC of 1000. 
Likewise, features not measured in any preeclampsia patients were assigned a FC of 0.001. 
Resulting FC values were log2-transformed, and then used to filter features by requiring FC ³ ± 
log2(1.5). 
 
Genomic and epigenomic profiling of the placental samples 
Nucleic acids were extracted from the same placentas as used for the non-targeted analysis as 
previously described [18, 19]. In brief, a subsection (approximately 0.2g) was sliced from each 
frozen tissue samples on dry ice using a sterile dermal curette and washed in sterile 1x PBS to 
remove any potential blood contamination. Samples were then immediately homogenized in 
Buffer RLT containing b-mercaptoethanol using a TissueRuptor (Qiagen, Valencia, CA). 
Nucleic acids were extracted from the resulting homogenate using the AllPrep 
DNA/RNA/miRNA Universal Kit according to the manufacturer’s instructions (Qiagen), which 
yielded RNA sequences 18 nucleotides and greater in length as well as DNA from the sample 
tissue samples. Extracted DNA and RNA were quantified with a Nanodrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA) and RNA integrity verified with a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
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Genome-wide gene expression profiles were evaluated by labeling and hybridizing RNA 
samples to the Affymetrix GeneChipTM Human Gene 2.0 ST array as previously described [18, 
19]. This microarray assesses the relative expression levels of >25,000 mRNAs using 53,617 
probesets. Resulting gene expression data were normalized by robust multi-chip average [20] 
and log2-transformed prior to statistical evaluation. Genome-wide miRNA expression profiles 
were evaluated by labeling and hybridizing RNA samples to the Agilent Human miRNA 
Microarray (v16) as previously described [19]. This microarray assesses the relative expression 
levels of 1347 miRNAs using 56,044 probesets. Resulting miRNA expression data were 
collapsed according to individual miRNA using the median signal, normalized by quantiles, and 
log2-transformed prior to statistical evaluation, as done previously [19, 21]. 
 
Genome-wide CpG methylation profiles were evaluated using the InfiniumÒ 
HumanMethylation450 BeadChip array (Illumina, Inc., San Diego, CA) as previously described 
[18]. This array assesses the CpG methylation levels of 486,428 sites across the DNA at single 
nucleotide resolution. Prior to array hybridization, DNA was first bisulfite-converted using the 
EZ DNA methylation kit (Zymo Research, Irvine, CA). Resulting methylation array data were 
produced as b values, where b = intensity of the methylated allele (M) / (intensity of the 
unmethylated allele (U) + intensity of the methylated allele (M) + 100). Data were pre-processed 
in accordance with an established 450k Chip Analysis Methylation Pipeline [22]. Probes within 
sites of known single nucleotide polymorphisms were removed, as were probes with detection p-
values > 0.01 to control for probe quality, leaving 390,452 probes that were then quantile 
normalized prior to statistical evaluation. 
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All genomic and epigenomic data were analyzed for quality assessment and quality control using 
standard measures [23], including visualizations of signal-to-noise ratio, root-mean-square-
deviation, MA plots, and principal component analysis to identify potential chip/batch/positional 
effects and/or sample outliers. All array data were deposited into the National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus repository and publicly available 
under accession numbers GSE73374, GSE73375, and GSE84260 [24].  
 
Statistical analysis to identify preeclampsia-relevant genomic and epigenomic alterations 
associated with APAP 
To identify potential molecular changes associated with APAP, genomic and epigenomic 
signature placenta tissue data were evaluated in relation to the chemical identified as high 
priority through non-targeted analysis, APAP. APAP concentrations (log2-transformed) were  
statistically related to gene expression, miRNA expression, and CpG methylation signatures 
from the same placenta samples. The placental genomic and epigenomic signature data were first 
filtered to focus on molecules with known association to preeclampsia based on our previously 
published analyses (and thus referred to as ‘preeclampsia-relevant’) [18, 19]. Specifically, 730 
genes (represented by 776 probesets with known gene-level annotations) and 631 miRNAs were 
identified with expression levels in the placenta associated with preeclampsia within this cohort. 
Similarly, 617 genes (represented by 695 probesets with known gene-level annotations) were 




Preeclampsia-relevant genes, miRNAs, and CpG sites were then evaluated in relation to APAP 
concentrations across the placenta samples to identify potential associated genomic/epigenomic 
alterations. Statistical approaches paralleled those that were previously implemented in the same 
cohort  [18, 19], wherein multivariable adjusted regression models were carried out. Potential 
confounders (e.g., maternal age, gestational age, newborn sex, parity, and race) were examined 
for potential association with both the independent and dependent variables. Each model 
controlled for gestational age, as this was the only covariate significantly associated with 
preeclampsia case status in this cohort (Supplemental Materials, Table S1), and it has 
published relationships with environmental exposures [25-28] and genomic/epigenomic 
signatures in placental tissues [29-31]. Furthermore, this covariate was used in our previously 
published analyses [18, 19]. 
 
Regression modeling was carried out in R (v3.6.0) using the lm function (stats v3.6.2) [32], with 
APAP concentration as the independent variable and the genomic/epigenomic endpoints as 
dependent variables. Resulting p-values were corrected for multiple test comparisons using the 
q-value statistic through the qvalue function (v2.18.0) in R [33]. Significant differential 
expression or methylation was defined using a false discovery rate (FDR) corrected q-value <0.2 
(p-value <0.05) for associations with APAP concentration. Additional filters were applied to 
consider the magnitude of change in expression or methylation. For these filters, the “highest 
exposed quartiles” (HEQ) and “lowest exposed quartiles” (LEQ) were identified for APAP 
exposure and used to calculate fold changes (FC) or beta differences, for expression and 
methylation analyses, respectively. For the gene and miRNA expression analyses, a filter 
requiring a FC ³ ± 1.5 was applied, where FC was defined as the ratio of the average expression 
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levels across the HEQ over the average expression levels across the LEQ. For the CpG 
methylation analyses, a filter requiring a beta difference ³ ± 0.10 was applied, where beta 
difference was defined as the average beta values across the HEQ subtracted by the average beta 
values across the LEQ. These calculations and statistical approaches are established and have 
been implemented by our research team in previous investigations using human 
genomic/epigenomic data [21, 34, 35]. Probesets (and their representative genes/miRNAs) that 
met these statistical criteria were identified as significantly associated with APAP. Significant 
genes/miRNAs were thus referred to as: differentially expressed genes (DEGs), differentially 
expressed miRNAs (DEMs), and differentially methylated genes (DMGs). 
 
Pathway and network enrichment analysis of genomic and epigenomic profiles associated 
with APAP from placenta tissues 
Biological pathway and network enrichment analyses were carried out to further investigate the 
biological implications of the genomic and epigenomic alterations associated with APAP. The 
lists of DEGs, DEMs, and DMGs were evaluated separately for enrichment of canonical 
pathways, as enabled through the Ingenuity Knowledge Database [36]. Over-represented 
pathways were defined as those that contained more APAP-associated molecules than expected 
by random chance, calculated from a right-tailed Fisher’s Exact Text [36]. Pathways with 
enrichment p-values<0.05 were considered significant, and top-ranking pathways were identified 
as those that were enriched within at least two of the three gene lists evaluated (i.e. two of the 
three lists of DEGs, DEMs, or DMGs). Networks were also constructed based on known protein-
protein and other molecular interactions to further elucidate biological signaling that may be 
impacted by APAP in preeclamptic pregnancies. For this network analysis, a collective list of all 
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DEGs, DEMs, and DMGs was used. Networks were ranked based on right-tailed Fisher’s Exact 
test p-values, indicating the likelihood of observing a network containing at least the same 
number of proteins encoded by APAP-associated genes by chance in comparison to random 
selections of genes [36]. The methods used in this analysis parallel those from our previous 
publications [21, 34, 37]. 
 
Chemical confirmation 
To confirm the presence of APAP identified at increased concentrations in preeclamptic tissues, 
a targeted analysis was carried out using an additional set of samples, labeled standards, and an 
alternative MS platform. Specifically, an additional set of samples were excised from the same 
placental tissues using the same extraction methods as previously described. Here, 25 μg/mL 
(ppm) labeled APAP (acetaminophen-D4 solution, Millipore Sigma, Darmstadt, Germany) was 
added at a volume of 20μL to each 0.5 grams of sample prior to extraction. Samples were rested 
on ice for 30 minutes and then extracted. A method blank containing only labeled APAP, and a 
solvent blank were included. 
 
The homogenized samples containing d4-APAP were analyzed using a high-resolution LC-
MS/MS assay. Upon analysis, all sample extracts were dried in a CentriVap vacuum 
concentrator (Labconco, MO, USA) and reconstituted in an equivalent volume of 
acetonitrile:water (2:98, v/v). A Vanquish UHPLC system coupling to high-resolution Q 
Exactive mass spectrometer was used (Thermo Fisher Scientific, MA, USA), featuring a 15-min 
chromatographic separation on an Acquity HSS T3 column (Waters, Milford, MA, USA), 
positive electrospray ionization (ESI), and parallel reaction monitoring (PRM) for parent APAP 
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(m/z 152.0706à110.0600) and labeled d4-APAP (m/z 156.0957à114.0851) under an HCD 
NCE of 60. Internal standard quantitation was used to determine placental APAP concentration 
levels, using two calibration curves that were respectively plotted for high APAP samples with 
ASD/ISD ratio>0.2 (12 points, 0.5 pg-2 ng on column, R2=0.9998) and for low APAP samples 
with ASD/ISD ratio<0.2 (5 points, 0.5-10 pg on column, R2=0.9979). The assay was sensitive 
and robust during the analysis, with RSD<5% monitored for both d4-APAP and APAP/d4-APAP 
ratios (n=5). As indicated by d4-APAP, sample recovery rates ranged from 87.8% to 130.6% 
with a mean of 108.3%, and no observable matrix effects were seen throughout the LC-MS/MS 
assay. 
 
The LOD for this analysis was 0.5 µg APAP/kg tissue. When tissues showed APAP 
concentrations below this LOD, values were imputed using the same approach as used in the 
non-targeted analysis, resulting in values of 0.3535 µg APAP/kg tissue as measures of 
concentration that were below the detection limit. 
 
In vitro tests to further characterize molecular changes associated with APAP exposure 
Effects of APAP were further evaluated through the use of in vitro testing using the human 
placental SVneo cell line, to specifically evaluate potential effects on cell death related 
processes. Pure APAP and stock solutions were created by dissolving in Dimethyl sulfoxide 
(DMSO). Cell culture media containing APAP treatments were prepared immediately before 
application to cells. Pure etoposide and stock solutions were created by dissolving in Dimethyl 
sulfoxide (DMSO). Etoposide is used as a positive control throughout in vitro experimentation as 
it has been shown to induce apoptosis among many cell lines [38-40]. The human placental 
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SVneo cell line, a well-established trophoblast lineage, was selected because they provide a 
reliable model for placental function [41]. Trophoblasts lineages such as SVneos represent the 
primary placental cell type and have been used extensively in research investigating cell 
proliferation, migration, and invasion. SVneos are thus useful cells for investigation of abnormal 
placentation and vascularization related to preeclampsia [42-44]. SVneo cells (ATCC) were 
cultured in serum media (RPMI 1640, Gibco, Grand Island, NY) containing 10% fetal bovine 
serum, 1% Sodium Pyruvate and 1% Pen/Strep.  
 
Western blotting for in vitro testing 
Western blot screening was performed with APAP-treated SVneo cells in order to evaluate 
potential changes in protein expression involved in cell death signaling. Cells were harvested 
following a 24 h treatment with 1M APAP, or 1 µM and 10µM etoposide. Whole cell lysates 
were harvested in 150 µL of RIPA buffer (Fisher Scientific) and protein quantity was determined 
using the Pierce Bicinchoninic Acid Method assay kit according to the manufacturer’s protocol 
(Thermo Scientific). All western blot materials were from Bio-Rad Laboratories (Hercules, CA) 
unless otherwise stated. Samples containing 25 µg of protein were combined with 2x Laemmli 
sample buffer containing 5% b-mercaptoethanol and loaded onto Tris-HCl gels, 
electrophoretically separated, and transferred to nitrocellulose membranes. After membranes 
were blocked with 5% nonfat milk dissolved for 30 minutes at 37°C degrees, membranes were 
incubated overnight at 4°C with primary antibodies to detect poly (ADP-ribose) polymerase 
 (PARP) antibody (9542), an apoptotic protein, from Cell Signaling Technologies at a 1:500 
dilution. Following overnight incubation at 4°C, the membrane was washed and incubated in 
either secondary Anti-rabbit HRP-linked Antibody (7074) from Cell Signaling Technologies at a 
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1:500 dilution for 1 hour at room temperature. Antibody-protein complexes were then visualized 
using Supersignal West Femto Maximal Sensitivity Reagent (Thermo Scientific) and an Imager 
(C-Digit) with Image Studio Digits software.  
 
Annexin V-FITC/Propidium Iodine Apoptosis Assay for in vitro testing  
The Annexin V-FITC/Propodium Iodine Apoptosis Assay was used to evaluate potential effects 
of APAP treatment on apoptosis signaling in SVneo cells. Cells were treated with serum media + 
APAP at three doses (100 µg/mL, 200 µg/mL, and 1000 µg/mL) or serum media + Etoposide at 
two doses (1 µg/mL and 10 µg/mL) in quadruplicates for each individual treatment 
condition/dose. After 48 hours, cells were trypsonized and collected, spun down, and 
resuspended in PBS to attain a concentration of ~2x106 cells/mL. Cells were stained with 
Annexin V-FITC and Propidium Iodine according to manufacter’s protocol (Nexcelom). 
Annexin V binds to phosphatidylserine which is normally only found on the inner plasma 
membrane in healthy cells, but during early apoptosis, is found externally. Propidium Iodide 
solution permeates cells with compromised cell membranes and binds to DNA which allows for 
differentiation between apoptotic, necrotic, and healthy cells. Cells were analyzed for 
fluorescence of these dyes using the Cellometer Spectrum Image Cytometry System (Nexcelom). 
 
Gene expression for in vitro testing 
Gene expression profiles relevant to placental cell health and death-relevant mechanisms were 
evaluated in APAP-treated cells. At 48 hours post-seeding, cells were treated with serum media 
+ APAP at 3 doses (100 µg/mL, 200 µg/mL, and 1000 µg/mL) or serum media + Etoposide at 2 
doses (1 µg/mL and 10 µg/mL) in quadruplicates for each individual treatment condition/dose. 
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After 24 and 48 hour time intervals, cells were collected for RNA in buffer RLT plus and 
extracted using the Qiagen AllPrep DNA/RNA/miRNA Universal Kit and concentrated using a 
Zymo Research clean and concentrator kit. Gene expression was measured using qPCR 
performed with the Fluidigm Biomark HD platform though the UNC Chapel Hill School of 
Medicine Advanced Analytics (AA) Core Facility, which simultaneously measured 48 genes and 
48 TaqMan mRNA probes provided in Supplemental Materials Table S4. This list included 
genes that are demonstrated markers of apoptosis, cell cycle, proliferation, migration, and 
literature-supported APAP induced changes in order to investigate possible mechanisms of 
APAP-induced changes in cell death and cell signaling. Altered genes shown to be associated 
with APAP and preeclampsia within the human placenta samples were also used to evaluate 




Chemicals identified in the placenta in preeclamptic pregnancies 
This study implemented a non-targeted approach to identify molecular features within a set of 
human placenta tissues from a cohort of preeclamptic (N=18) and normotensive (N=17) 
pregnancies. Features were identified with high confidence as based on matching MS/MS 
fragmentation data within the Agilent PCDL database. A total of 83 molecular features were 
identified in at least one sample, representing 68 unique chemicals (Figure 1A). The 
distributions of feature abundances were evaluated for significant differential distributions 
between preeclamptic vs. normotensive pregnancies. As a result, 29 features representing 27 
unique chemicals were identified as showing significant differences in abundance levels between 
the two conditions. (Figure 1B, Table 1). 
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Figure 1. Molecular features that mapped to chemicals within the PCDL database.   
 
 (A) A total of 83 molecular features were detected in the placenta samples that mapped to 
known chemical identifiers, as shown by a bubble plot. Each feature is represented by a circle, 
with diameter proportional to average abundance. (B) A total of 29 molecular features had 
abundance levels that changed significantly according to preeclamptic case status, as shown by 









Table 1. 27 chemicals, represented by 29 molecular features, identified with abundance levels 
associated with preeclamptic (PE) vs. normotensive (CT) pregnancies. Features are sorted by 
lowest to highest p-value. Abbreviations: DSSTox, Distributed Structure-Searchable Toxicity; 
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C23H45NO4 17 18 35 1.99 2.60E-04 







C9H17NO4 17 18 35 1.37 4.59E-04 
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E-03 






4S3 0 9 9 9.97 
1.33
E-03 






4S3 0 10 10 9.97 
2.50
E-03 






C4H9N3O2 17 18 35 0.80 4.02E-03 




5 17 18 35 0.83 
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C7H15NO3 16 16 32 0.85 5.65E-03 











C4H6O4 17 18 35 0.69 5.66E-03 
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E-02 
Val Leu NA VAL-LEU DTXSID00874268 Metabolite 
C11H22N2O
3 14 17 31 2.94 
3.13
E-02 
L-Glutamate 56-86-0 L-Glutamic acid 
DTXSID5020
659 Amino acid  C5H9NO4 17 17 34 0.60 
3.51
E-02 




































1763 Metabolite C18H37NO2 17 18 35 0.73 
6.19
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C4H8O5 16 17 33 0.65 7.33E-02 
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Of high pertinence to the current analysis, Palmityl-L-carnitine, Acetylcarnitine, Adenosine, 
Betaine, and APAP were identified at abundance levels most significantly increased in 
association with preeclampsia.  Here we selected APAP as a chemical to prioritize for further 
analyze using additional technologies and approaches due to the following lines of evidence: (1) 
APAP showed significantly increased abundance levels in placentas from preeclamptic vs. 
normotensive pregnancies (Figure 2A), and (2) APAP represents a pharmaceutical that is 
commonly taken during pregnancy [45, 46].  
 
Given the confirmed presence of APAP in several placenta samples, observed molecular features 
were also screened for the presence of N-acetyl-p-benzoquinone imine (NAPBQI), a known 
toxic metabolite of APAP. A feature matching the monoisotopic mass and molecular formula of 
NAPBQI was observed in the prefiltered ESI+ data files, but not in the WebApp processed data 
files. This feature that matched NAPBQI’s monoisotopic mass and molecular formula appeared 
in nearly every sample in both patient groups at very stable intensity levels, and thus did not 
track with APAP levels. This feature was also present in the method blank samples at intensity 
levels indistinguishable from those observed in study samples. As such, the feature in question 
was determined to be a background feature and not related to APAP. Based on these results, the 







APAP confirmation in placentas from preeclamptic pregnancies 
The concentrations of APAP in placentas from this cohort were confirmed using targeted 
approaches with an additional set of excised samples and an alternative MS platform, namely, a 
high-resolution orbitrap LC-MS. This additional analysis integrated labeled standards to allow 
for concentration derivations from these tissues. With this approach, APAP was measured at 
concentrations ranging from below detection (0.5 µg APAP/kg tissue) to 3668 µg APAP/kg 
tissue (average=442, standard deviation=997.5 µg APAP/kg tissue) (Figure 2B). These 
concentrations notably correlated with the abundance measures derived from the non-targeted 
analysis (Figure 2C). 
 
Figure 2. APAP was measured at significantly increased levels in tissues from preeclamptic vs. 
normotensive pregnancies through two analytical approaches. 
 
(A) Abundance levels were obtained using non-targeted approaches with high-resolution LC-
qTOF and (B) confirmed using targeted approaches with high-resolution orbitrap LC-MS. (C) 
APAP concentrations were significantly correlated between these two approaches. (*) indicates 
a significant difference (p<0.01). 
 
APAP-associated genomic and epigenomic disruptions in placenta 
To identify potential genomic/epigenomic alterations associated with APAP, concentrations of 
APAP were statistically related to gene, miRNA, and CpG methylation signatures within the 
exact same tissues. Then, these molecules were evaluated for expression or methylation 
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alterations associated with APAP. APAP concentrations were identified as associated with the 
differential expression of 27 genes, differential expression of 57 miRNAs, and differential 
methylation of 18 genes of relevance to preeclampsia (Supplemental Material Table S2). 
 
To further investigate the functional implications of placental -omic alterations, biological 
function enrichment analyses were carried out on the preeclampsia-relevant genes, miRNAs, and 
CpG methylation sites with differential expression or methylation associated with APAP. Several 
canonical pathways were identified as significantly associated with the APAP-associated -omic 
alterations (Table 2), with organismal injury and abnormalities showing the most significant 
enrichment (ave p-value across all gene lists = 4.08 x 10-5). Other highly enriched functions 
included cell death and survival (ave p-value = 1.81x10-4), cell compromise (ave p-value = 
4.91x10-4), and cell cycle (ave p-value = 6.45x10-4). Protein-protein interaction networks were 
also constructed based on known and predicted molecular interactions between the APAP-
associated gene lists and related biological signaling. The two most significant networks 
constructed based on the multi-omic responses contained signaling relevant to cell compromise, 
cell death and survival, and cell cycle (Figure 3A and 3B). Relevant proteins of interest within 
these networks included those encoded by genes with differential expression (e.g., thioredoxin 
interacting protein [TXNIP]), genes with differential methylation (e.g., BCL2 antagonist/killer 1 






Table 2.  Biological functions and diseases that are highly enriched amongst preeclampsia-
relevant differentially expressed genes (DEGs), differentially expressed microRNAs (DEMs), 
and differentially methylated genes (DMGs) associated with acetaminophen levels in placenta 
tissues. The 20 top-ranking disease/function categories are listed, with the most significantly 
associated categories (on average) listed at the top. 
Biological Function or 
Disease Category 
Average p-value 
across DEGs,  
DEMs, and DMGs 
DEGs p-value DEMs p-value DMGs p-value 
Organismal Injury and 
Abnormalities 
4.08E-05 1.54E-05 1.04E-12 1.07E-04 
Cancer 4.14E-05 1.54E-05 1.76E-06 1.07E-04 
Cell Death and Survival 1.81E-04 1.23E-04 NS 2.38E-04 
Cellular Compromise 4.91E-04 2.14E-04 NS 7.67E-04 
Reproductive System 
Development and Function 
5.24E-04 2.80E-04 NS 7.67E-04 
Hereditary Disorder 5.81E-04 2.83E-04 6.93E-04 7.67E-04 
Inflammatory Disease 6.02E-04 1.04E-03 1.04E-12 7.67E-04 
Inflammatory Response 6.02E-04 1.04E-03 1.04E-12 7.67E-04 
Immunological Disease 6.07E-04 1.04E-03 1.42E-05 7.67E-04 
Neurological Disease 6.07E-04 1.04E-03 1.42E-05 7.67E-04 
Cell Cycle 6.45E-04 1.04E-03 4.92E-04 4.04E-04 
Cellular Movement 7.66E-04 1.04E-03 4.92E-04 7.67E-04 
Hair and Skin Development 
and Function 
8.25E-04 8.83E-04 NS 7.67E-04 
Developmental Disorder 8.33E-04 1.04E-03 6.93E-04 7.67E-04 
Cellular Assembly and 
Organization 
9.04E-04 1.04E-03 NS 7.67E-04 
Cardiovascular Disease 9.07E-04 2.83E-04 NS 1.53E-03 
Tissue Morphology 1.16E-03 7.85E-04 NS 1.53E-03 
Ophthalmic Disease 1.29E-03 1.04E-03 NS 1.53E-03 
Small Molecule Biochemistry 1.29E-03 1.04E-03 NS 1.53E-03 








Figure 3. Integrated -omic networks showing APAP-associated changes relevant to cell 
compromise and cell death. The two most significant networks are displayed (A and B) showing 
likely interactions between genes, miRNAs, and CpG sites that were identified with differential 
expression or methylation associated with APAP. 
 
 
Molecular testing of APAP-induced mechanistic changes in placenta cells  
The ability of APAP to induce changes in cell death was evaluated through several approaches 
using SVneo cells treated with APAP at concentrations ranging from 0 to 1000 uM. These 
concentrations included those that were than measured in human tissues, as well as 
concentrations higher than the measured concentrations. Specifically, when using a density of 







































































Apoptosis was first assessed in SVneo cells treated with APAP and Etoposide by assessing 
expression of PARP protein via western blot. The analysis of SVneo cells demonstrated that only 
positive controls treated with the high-dose etoposide expressed PARP cleavage, with no 
detectable cleavage among APAP-treated cells (Figure 4). 
 
Figure 4. Characterization of PARP expression in APAP Etoposide treated SVneo cells. PARP 
antibody detected endogenous levels of full length PARP1 as well as the large fragment of 





To further elucidate the relationship between APAP exposure and mechanisms of cell death of 
SVneo cells using a more global approach, cells were analyzed using the Annexin V-
FITC/Propidium Iodine Apoptosis Assay. Pilot results of this assay showed no significant 
changes in apoptosis among cells treated with APAP in comparison to the negative or positive 
control in the 48 hours treatment (Figure 5A and 5B). However, the total percent of 
necrotic/dead cells among the APAP 1000μM and 200μM was significantly increased in 
comparison to the control group (Figure 5C). This finding suggests that necrosis may be the 





Figure 5. Analysis of apoptotic, late-stage apoptotic/necrotic, and dead SVneo cells A) Percent 
of apoptotic cells as characterized by being FITC Annexin-V positive and PI negative, B) ) 
Percent of late stage-apoptotic or necrotic as characterized by being both FITC Annexin-V 
positive and PI positive, and C) Percent of dead or necrotic cells  as characterized by being 




To further establish the relationship been APAP and biological processes such as cell cycle, 
apoptosis, proliferation, migration, and cell death in-vitro, 48 genes were selected for expression 
analysis, 10 of which overlapped with those significantly associated with APAP among human 
placental samples (Supplemental Material Table S3). Treatment of SVneo cells with 100 μM, 
200 μM, and 1000 μM of APAP resulted in 13 genes found to be significantly differentially 
expressed in APAP treated cells in comparison to the control group. Of high interest, the genes 
DnaJ Heat Shock Protein Family Member C3 (DNAJC3), Phospholipase A2 Group VII 
(PLA2G7), Protein Tyrosine Phosphatase Non-Receptor Type 13 (PTPN13), Thioredoxin 
Interacting Protein (TXNIP), and Ubiquitin C (UBC) were found to be differentially expressed in 





Figure 6. Gene expression analysis of APAP treated placental cells shows 5 significant genes 
differentially expressed when compared to control group (* indicates significance)  
 
These findings have important implications for the role of APAP in cell death, cell cycle, 
migration, and preeclampsia.  
 
DISCUSSION 
In the present study, we implement a non-targeted analysis of placentas from normotensive and 
preeclamptic pregnancies to identify potentially understudied chemicals associated with this 
serious pregnancy outcome. The evaluation of xenobiotic chemicals as part of the prenatal 
exposome is of high interest, as exposure to xenobiotics during pregnancy is becoming 
increasingly recognized as an important risk factor for pregnancy-relevant health outcomes such 
as preeclampsia [1]. Our analysis identified 68 unique chemicals with high confidence among the 
placenta samples, 27 of which were associated with preeclampsia. Among the chemicals 
associated with preeclampsia, APAP was identified as a chemical of high interest due to its 
significant increase in concentrations measured in samples from preeclamptic vs. normotensive 
patients, as well as its common use during pregnancy, making it important to further evaluate. 
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This serves as an important proof of concept and led to subsequent molecular testing of APAP in 
placental cells evaluating potential mechanisms related to the onset or maintenance of 
preeclampsia.  
 
This study utilized placental tissue from normotensive and preeclamptic pregnancies to evaluate 
potential relationships between chemical exposures and preeclampsia case status. Previous 
studies have evaluated chemicals such as perfluoroalkyl and polyfluoroalkyl substances, lead, 
and cadmium in maternal serum and/or fetal cord blood & related them to preeclampsia [48-50]. 
Few studies, however, have investigated chemical concentration in the placenta, representing an 
important target tissue involved in preeclampsia etiology; and these studies have implemented 
targeted approaches to evaluate select chemicals. For example, Laine et al. investigated a cohort 
of 172 placental samples, 86 of which were from preeclamptic pregnancies, and found that 
concentrations of cadmium in placental tissue were significantly associated with preeclampsia 
case status [5]. Here, we implement a novel non-targeted method to expand the current 
understanding of relationships between chemicals reaching the placenta and preeclampsia. This 
method resulted in the detection and identification of 68 unique chemicals that contribute to the 
growing knowledge of the placental exposome. Among these chemicals, 27 had concentrations 
significantly associated with preeclamptic pregnancies. One of the chemicals identified with the 
most significantly increased levels associated with preeclampsia was APAP, which was 
prioritized for further evaluation.   
 
To evaluate molecular changes associated with APAP, potential genomic and epigenomic 
alterations were evaluate in relation to APAP in the same placenta tissues. Pathway analysis of 
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genomic and epigenomic alterations associated with APAP showed enrichment for important 
cellular processes such as cell death and survival, cellular compromise, reproductive system 
development and function, and cell cycle among others. Of pertinence to these signaling 
changes, we identified increased expression of genes such as TXNIP and PTPN13, differential 
methylation of genes such as BAK1, and differential expression of miRNAs such as miR-132-3p 
and miR-193a-3p. Overexpression of TXNIP has been shown to reduce proliferation and induce 
apoptosis in beta-cells [51, 52]. Similarly, the protein encoded by BAK1 has been shown to be 
pro-apoptotic [53-55]. PTPN13 is also linked to the induction of apoptosis, as well as cell 
proliferation and migration [56-58] An example miRNA, miR-193a-3p, had increased expression 
significant with APAP and is of interest due to its potential ability to inhibit proliferation, 
migration, and invasion of cells [59]. These example genetic and epigenetic-level changes 
highlight potential mechanistic targets that may serve as a link between APAP and preeclampsia 
disease etiology. 
 
Previous studies also support an association between APAP and altered pregnancy-related health 
outcomes such as preeclampsia. A large study consisting of 63,833 participants identified an 
association between APAP use during third trimester and increased risk of preeclampsia [60]. 
Another study consistent with our findings reported that prenatal APAP exposure induced 
placental damage in mice following injection with a dose 250 mg/kg APAP, comparable to a 
dose slightly higher than the recommended single dose for humans [61]. These findings 
warranted further mechanistic evaluation of APAP using more controlled study designs, as 
available through in vitro assessment.  
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Given cell death and survival was shown to be one of the most significantly enriched pathways 
among our tissue samples, placental cells were treated in vitro and evaluated for several potential 
changes in cell death-relevant signals in order to further evaluate cell death resulting from 
exposure to APAP in the placenta. For example, the expression of PARP protein was assessed. In 
general, the PARP protein assists the maintenance of cell viability while cleavage of PARP 
serves as a marker of cells undergoing apoptosis [62]. Though we found no evidence of PARP 
cleavage among APAP treated cells, a non-specific approach utilizing FITC Annexin-V and PI 
staining for investigating apoptotic versus necrotic death was also implemented to account for 
other mechanisms of cell death that may be occurring. The results of this pilot experiment further 
supported that apoptosis may not be occurring as result of APAP exposure, alone, in the SVneo 
cell line. This finding is novel in that, to our knowledge, apoptosis resulting from APAP 
exposure has not yet been testing within the SVneo cell line. Further testing utilizing larger 
sample sizes and a more comprehensive range of dosing is required to draw definitive 
conclusions. What remains to be tested is whether APAP was converted into its more toxic 
metabolite, NAPBQI, within these cells under these conditions, and whether NAPBQI can 
influence PARP expression and other apoptotic mechanisms directly in placental cells in vitro. 
 
While the role of apoptosis in hepatocyte cytotoxicity resulting from APAP exposure is highly 
debated, our findings are supported by previous studies that have found necrosis to be the 
primary pathway of hepatotoxicity resulting from APAP overdose [63, 64]. For example, a 
previous study in vivo evaluated hepatocyte injury after APAP treatment of 300 mg/kg in mice. 
Apoptotic and necrotic hepatocytes were quantified and the percent apoptotic cells remained 
below 1% of all cells, whereas necrotic cells involved between 40% and 60% of all hepatocytes 
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[65].  Our global analysis of apoptotic, late-stage apoptotic, and necrotic cells, supported a 
general increase in necrotic cell deaths among placenta cells treated with APAP in comparison to 
control groups. These results warranted further investigation into alternative pathways of 
placenta cell death from APAP exposure through the utilization of gene expression analysis.  
 
Our in-vitro gene expression analysis evaluated a panel of genes that play various roles in cell 
cycle, cell death, proliferation and other preeclampsia-relevant functions. The treatment and 
analysis of placental cells provided further evidence that APAP is related to the differential 
expression of several genes, 5 of which overlapped with those found to be differentially 
expressed in placental tissue samples.  The five genes, DNAJC3, PLA2G7, PTPN13, TXNIP, and 
UBC had increased expression among both placental tissue samples and in APAP treated SVneo 
placental cells, demonstrating similar APAP-associated changes in vitro and in human placental 
cells. These genes play important roles in apoptosis, proliferation, and cell cycle  [51, 52, 56-58, 
66-72] and thus the altered expression of these genes have potential implications for the 
relationship between APAP exposure and preeclampsia disease etiology.  
 
As aforementioned, the metabolism of APAP into its toxic biproduct NAPBQI within the SVneo 
cell-line remains to be tested. It is well established that APAP cytotoxicity in hepatocytes results 
in part from the overabundance of highly reactive metabolite NAPBQI [64]. At non-toxic doses 
glucuronide and sulfate conjugation enzymes effectively metabolize this compound but higher 
doses, NAPBQI’s metabolic pathways become over-saturated and NAPQI is left to react with 
liver cells, often causing cell damage and death [73]. One mechanism by which  
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NAPQI interacts with hepatocytes is by the irreversible formation of protein adducts leading to 
oxidative injury and cell death by necrosis [74]. While we were unable to detect this highly 
reactive metabolite among our placenta samples through analytical techniques, future studies 
may evaluate acetaminophen–induced placental toxicity by measuring more stable metabolic 
products of acetaminophen such as NAPQI-protein adducts to further characterize how 
acetaminophen may influence placental cell health and survival.  
 
Pregnant women are often advised to avoid nonsteroidal anti-inflammatory drugs and opioids 
during pregnancy, thus APAP is left as one of the few pain killers approved for use during 
pregnancy [75]. This cohort was a high-risk pregnancy cohort and thus it is possible patients 
were experiencing more pain, leading to increased intake of APAP. Because severe headaches 
are one of the most common symptoms of preeclampsia, reverse-causation remains a plausible 
explanation for the significant difference in concentrations between preeclamptic vs. 
normotensive patients [76]. This serves as an important proof of concept for our analytical 
testing methods and establishes a protocol for future testing of other chemicals. With additional 
toxicokinetic data supporting the ability of APAP to reach placental tissues, we have further 
evidence supporting our finding that APAP is the chemical corresponding to the detected 
molecular feature among placental samples [77, 78]. We also recognize this study is a pilot study 
based on 36 subjects, however our findings remain robust as we analyzed each placenta sample 
extensively, in high dimensionality using global approaches through chemical speciation, 
genomic profiling, and epigenomic profiling within the same samples. The application of 
stringent statistics to the relationships observed gives us high confidence in the data presented. 
Future studies may expand on this study through larger cohort designs.  
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In conclusion, this research provides novel evidence towards characterizing chemicals in the 
placental and identified APAP as one of the most significantly associated compounds related to 
preeclampsia. Mechanistic findings showed changes in gene expression relevant to placental cell 
damage and cell death that may be relevant to preeclampsia etiology and support the need for 
further investigation.  This study serves as an important foundation to further elucidate 
relationships between potential chemical exposures and placental health in pregnant women.    
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Table S1. Study cohort demographic information. Overall characteristics of the study cohort 
are provided for all participants, controls (normotensive patients), and cases (preeclamptic 
patients). 
 
Characteristics All N (%) /  Controls N (%) /  Cases N (%) /  p-value 
(Cases vs. 
Controls) Mean (range) Mean (range) Mean (range) 
Subjects 35 17 18   
Race       0.196 
African American 13 (37%) 5 (29%) 8 (44%)   
Asian 2 (6%) 2 (12%) 0 (0%)   
Caucasian 10 (29%) 5 (29%) 5 (28%)   
Hispanic 7 (20%) 5 (29%) 2 (11%)   
Other 3 (9%) 0 (0%) 3 (17%)   
Parity       0.519 
Primipara 20 (57%) 9 (53%) 11 (61%)   
Multipara 15 (43%) 8 (47%) 7 (39%)   
Smoking Status       0.548 
Smoker 3 (9%) 1 (6%) 2 (11%)   
Non-Smoker 32 (91%) 16 (94%) 16 (89%)   
Maternal Age (years) /28.2 (19-38) /27.5 (19-38) /28.6 (19-37)   
Newborn Sex       0.9809 
Male 19 (54%) 5 (29%) 12 (67%)   
Female 21 (60%) 12 (71%) 6 (33%)   









Table S2. Lists of -omic alterations relevant to preeclampsia that were identified as 
associated with acetaminophen. (A) Differentially expressed genes (DEGs), (B) differentially 
expressed microRNAs (DEMs), and (C) differentially methylated genes (DMGs) are listed 
alongside array probeset identifiers and pertinent statistics describing relationships to 
acetaminophen levels measured in placenta tissues. Abbreviations: FDR: false discovery rate; 
FC: fold change, as calculated as the ratio of the highest exposed quartile (HEQ) / the lowest 
exposed quartile (LEQ); NA: not applicable. Beta difference values were calculated as the 




Gene Symbol ProbeSetID p-value FDR q-value log2FC (HEQ/LEQ) 
TXNIP  16669796 2.2E-02 1.6E-01 1.03 
HIST2H2AA4   16670383 4.9E-02 1.6E-01 0.69 
HSD11B1  16676988 3.4E-02 1.6E-01 1.84 
CTSK  16692846 3.9E-02 1.6E-01 0.94 
TMEM236  16702827 4.1E-02 1.6E-01 0.79 
EXT2  16724031 3.7E-02 1.6E-01 0.64 
UBC  16758874 4.8E-02 1.6E-01 0.69 
DNAJC3  16775856 4.0E-02 1.6E-01 0.90 
NID2  16792954 1.3E-02 1.6E-01 0.69 
SNRPN  16798246 3.7E-02 1.6E-01 0.85 
CHD9  16818927 3.8E-02 1.6E-01 0.82 
MFAP4  16842266 3.6E-02 1.6E-01 0.78 
ANTXR1  16881031 2.5E-02 1.6E-01 0.96 
OTTHUMG00000154620   16885819 1.2E-02 1.6E-01 0.75 
ADAMTS5  16924620 4.5E-02 1.6E-01 0.85 
TIMP3  16929442 5.0E-02 1.6E-01 0.85 
TM4SF1  16960355 3.0E-02 1.6E-01 1.04 
PTPN13  16968529 2.0E-02 1.6E-01 0.96 
ANTXR2  16977251 8.8E-04 1.6E-01 0.70 
PLA2G7  17019728 4.3E-02 1.6E-01 1.10 
TMEM30A  17020930 4.3E-02 1.6E-01 0.81 
CITED2  17024285 3.3E-02 1.6E-01 0.94 
OTTHUMG00000163653   17074071 2.0E-02 1.6E-01 -0.74 
CTSL1  17086540 2.7E-02 1.6E-01 1.12 
TTTY15  17116194 4.4E-02 1.6E-01 1.01 
USP9Y  17116200 4.7E-02 1.6E-01 1.07 
UTY  17116977 3.2E-02 1.6E-01 1.37 
(B) DEMs 
MicoRNA Name ProbeSetID p-value FDR q-value log2FC (HEQ/LEQ) 
hsa-miR-1226* NA 4.0E-03 1.5E-02 0.66 
hsa-miR-1234 NA 9.9E-04 8.4E-03 1.26 
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hsa-miR-1246 NA 1.3E-02 2.5E-02 -0.99 
hsa-miR-1280 NA 2.5E-02 3.8E-02 0.71 
hsa-miR-1281 NA 2.0E-02 3.3E-02 1.82 
hsa-miR-1290 NA 1.1E-02 2.2E-02 -1.29 
hsa-miR-1307 NA 4.3E-03 1.6E-02 1.32 
hsa-miR-134 NA 5.8E-03 1.8E-02 1.31 
hsa-miR-148a NA 1.5E-03 8.9E-03 0.87 
hsa-miR-151-3p NA 1.6E-02 2.9E-02 0.65 
hsa-miR-1825 NA 9.5E-05 3.1E-03 1.01 
hsa-miR-193a-3p NA 6.6E-03 1.9E-02 1.47 
hsa-miR-193b NA 2.1E-02 3.4E-02 0.62 
hsa-miR-19a NA 1.8E-02 3.0E-02 1.15 
hsa-miR-19b NA 1.9E-02 3.1E-02 1.10 
hsa-miR-202 NA 2.1E-02 3.4E-02 0.88 
hsa-miR-212 NA 2.0E-04 3.8E-03 0.87 
hsa-miR-3131 NA 2.4E-03 1.1E-02 3.26 
hsa-miR-3138 NA 1.5E-02 2.8E-02 -0.77 
hsa-miR-3154 NA 2.0E-02 3.2E-02 -0.72 
hsa-miR-3188 NA 2.9E-02 4.2E-02 0.73 
hsa-miR-3196 NA 1.0E-02 2.2E-02 0.91 
hsa-miR-320c NA 1.2E-02 2.4E-02 -0.92 
hsa-miR-335* NA 5.1E-03 1.7E-02 -0.86 
hsa-miR-3609 NA 1.5E-02 2.8E-02 -0.71 
hsa-miR-3622b-5p NA 5.2E-03 1.7E-02 -0.98 
hsa-miR-3659 NA 9.0E-03 2.1E-02 0.86 
hsa-miR-3660 NA 4.8E-02 5.9E-02 0.60 
hsa-miR-3663-5p NA 1.3E-02 2.5E-02 1.02 
hsa-miR-3667-5p NA 4.2E-02 5.4E-02 -1.02 
hsa-miR-371-5p NA 1.9E-02 3.1E-02 -0.84 
hsa-miR-3713 NA 4.2E-02 5.4E-02 -0.80 
hsa-miR-3937 NA 5.8E-03 1.8E-02 0.78 
hsa-miR-3945 NA 1.6E-02 2.8E-02 -0.95 
hsa-miR-4253 NA 3.2E-03 1.4E-02 1.10 
hsa-miR-4324 NA 8.5E-03 2.0E-02 -0.75 
hsa-miR-484 NA 6.3E-04 6.8E-03 0.71 
hsa-miR-513a-5p NA 3.5E-04 5.4E-03 -0.93 
hsa-miR-513b NA 7.3E-03 1.9E-02 -0.88 
hsa-miR-513c NA 5.1E-03 1.7E-02 -0.65 
hsa-miR-514b-5p NA 2.9E-02 4.2E-02 -0.74 
hsa-miR-517c NA 1.6E-02 2.8E-02 -0.59 
hsa-miR-548q NA 1.5E-02 2.8E-02 0.96 
hsa-miR-551b* NA 3.9E-02 5.0E-02 -0.64 
hsa-miR-572 NA 1.6E-03 9.1E-03 1.20 
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hsa-miR-601 NA 2.1E-03 1.1E-02 1.08 
hsa-miR-605 NA 6.4E-03 1.9E-02 0.91 
hsa-miR-636 NA 5.6E-04 6.3E-03 1.45 
hsa-miR-638 NA 1.1E-03 8.4E-03 0.95 
hsa-miR-663 NA 1.6E-02 2.8E-02 1.28 
hsa-miR-711 NA 4.7E-02 5.8E-02 -0.70 
hsa-miR-720 NA 1.0E-02 2.2E-02 1.48 
hsa-miR-877* NA 2.7E-02 4.1E-02 0.93 
hsa-miR-892b NA 9.5E-03 2.1E-02 0.70 
hsa-miR-933 NA 2.5E-02 3.9E-02 1.21 
hsa-miR-936 NA 3.6E-02 4.8E-02 -1.03 




CpG Site p-value FDR q-value Beta Difference 
OR1I1 cg00364445 8.9E-03 1.5E-02 0.12 
RERE cg01447281 1.4E-04 2.8E-03 -0.16 
IER3 cg13337949 2.4E-03 7.1E-03 -0.12 
MAGEB6 cg04730443 3.0E-02 3.0E-02 0.11 
ASAP2 cg05088820 2.0E-02 2.4E-02 -0.15 
MOG cg05913325 2.8E-02 2.9E-02 0.11 
DST cg06311422 2.8E-03 7.6E-03 -0.11 
TMEM97 cg06692120 3.0E-05 9.8E-04 -0.13 
MC1R cg23057051 8.2E-04 5.2E-03 -0.12 
MAGEB2 cg10079981 2.5E-02 2.7E-02 0.11 
LOC399959 cg10262710 4.7E-04 4.7E-03 -0.11 
SH3BP4 cg11677744 1.2E-03 5.6E-03 -0.10 
MTHFD1L cg16336494 3.0E-03 7.9E-03 -0.13 
MAGEB10 cg16821267 9.7E-03 1.5E-02 0.10 
PAPLN cg21885107 8.0E-04 5.2E-03 -0.11 
BAK1 cg24505687 2.3E-02 2.6E-02 -0.12 
MAD2L1 cg27080119 3.0E-04 3.9E-03 -0.11 












Table S3. Table of genes evaluated for expression in the SVneo cell line with justification 
for inclusion. 
 
Gene Symbol Justification for Inclusion 
ANTXR1  IPA cell cycle/cell death (inc. apoptosis) 
ANTXR2  IPA cell cycle/cell death (inc. apoptosis) 
BAD Marker of apoptosis/proliferation 
BAK Marker of apoptosis/proliferation 
BAX Marker of apoptosis/proliferation 
BCL-2 Marker of apoptosis/proliferation 
BCL2L1 Marker of apoptosis/proliferation 
BID Marker of apoptosis/proliferation 
CCNA1 Marker of apoptosis/proliferation 
CCNA2 Marker of apoptosis/proliferation 
CCND1 Marker of apoptosis/proliferation 
CCND2 Marker of apoptosis/proliferation 
CITED2  IPA cell cycle/cell death (inc. apoptosis) 
COX1 Literature supports role in APAP-induced changes 
COX2 Literature supports role in APAP-induced changes 
CTSL1  IPA cell cycle/cell death (inc. apoptosis) 
DNAJC3  IPA cell cycle/cell death (inc. apoptosis) 
E2F1 Marker of apoptosis/proliferation 
E2F2 Marker of apoptosis/proliferation 
E2F3 Marker of apoptosis/proliferation 
EGF Literature supports role in APAP-induced changes 
EGFR Literature supports role in APAP-induced changes 
EGR1 Marker of apoptosis/proliferation 
EIF2a Marker of apoptosis/proliferation 
FAS Marker of apoptosis/proliferation 
FASL Marker of apoptosis/proliferation 
FLT1 Marker of apoptosis/proliferation; onset of PE 
FOS Marker of apoptosis/proliferation 
FOSL2 Marker of apoptosis/proliferation 
GAPDH Loading control 
HIF1A Literature supports role in APAP-induced changes 
KI67 Marker of apoptosis/proliferation 
NID2  a cell-adhesion protein that binds collagens I and IV and laminin and may be 
involved in maintaining the structure of the basement membrane; broad 
expression in placenta 
PCNA Marker of apoptosis/proliferation 
PLA2G7  IPA cell cycle/cell death (inc. apoptosis) 
PLGF Loading control 
PTPN13  IPA cell cycle/cell death (inc. apoptosis) 
RPL13A Loading control 
SDHA Loading control 
TNFa Marker of apoptosis/proliferation 
TNFAIP3 Marker of apoptosis/proliferation 
TNFRSF1A Marker of apoptosis/proliferation 
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TNFSF10 Marker of apoptosis/proliferation 
TP53 Marker of apoptosis/proliferation 
TP53INP1 Marker of apoptosis/proliferation 
TXNIP  IPA cell cycle/cell death (inc. apoptosis) 
UBC  IPA cell cycle/cell death (inc. apoptosis) 
YWHAZ Loading control 
 
 
 
